Component
Supplemental oxygen requirement at 36 weeks postmenstrual age
Study-scoped entity; inspect species, exposure, model and limitations on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
At 36 weeks postmenstrual age, 36% of surviving caffeine-group infants required oxygen versus 47% with placebo; adjusted odds ratio 0.63.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo.
- limitations
- Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations.
- nutrient_topic
- Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
- plain_language
- Clinical caffeine treatment reduced an important neonatal respiratory outcome.
- primary_references
- Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065
Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 508–514
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. · source_derived_draft · unverified_draft
## caf-preterm-oxygen Clinical caffeine treatment reduced an important neonatal respiratory outcome. At 36 weeks postmenstrual age, 36% of surviving caffeine-group infants required oxygen versus 47% with placebo; adjusted odds ratio 0.63. Model: CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. Limitations: Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations. Evidence access: Primary abstract Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.